The safety of Bosutinib for the treatment of chronic myeloid leukemia

Jee Hyun Kong, H. Khoury, Audrey Sunwha Kim, Brittany Gray Hill, Vamsi Kota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Tyrosine kinase inhibitors (TKIs) are a potentially lifelong treatment for patients with chronic myeloid leukemia (CML). Adverse events (AEs) associated with TKIs are significant impediments in the daily life of patients that can impact compliance, and efficacy. Areas covered: This is a review on safety of bosutinib in the treatment of chronic phase CML. Data is extracted from the latest updates of bosutinib phase I/II and III trials. Expert opinion: Bosutinib is an effective agent against all phases of CML presently approved for the treatment in patients with resistance or intolerance to prior TKI therapy. Bosutinib has a unique toxicity profile characterized by early and transient diarrhea. Otherwise, the AE profile of bosutinib is comparable to other TKIs, with the exception of cardiovascular AEs that are infrequent in bosutinib-treated patients. Similar to other TKIs, the minimum effective dose of bosutinib remains unknown. Better definition of the optimal effective dose may spare, for those patients otherwise benefitting from treatment, unnecessary AEs.

Original languageEnglish (US)
Pages (from-to)1203-1209
Number of pages7
JournalExpert Opinion on Drug Safety
Volume16
Issue number10
DOIs
StatePublished - Oct 3 2017
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Safety
Leukemia, Myeloid, Chronic Phase
Therapeutics
Expert Testimony
bosutinib
Compliance
Diarrhea

Keywords

  • Bosutinib
  • chronic myeloid leukemia
  • efficacy
  • safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The safety of Bosutinib for the treatment of chronic myeloid leukemia. / Kong, Jee Hyun; Khoury, H.; Kim, Audrey Sunwha; Hill, Brittany Gray; Kota, Vamsi.

In: Expert Opinion on Drug Safety, Vol. 16, No. 10, 03.10.2017, p. 1203-1209.

Research output: Contribution to journalArticle

Kong, Jee Hyun ; Khoury, H. ; Kim, Audrey Sunwha ; Hill, Brittany Gray ; Kota, Vamsi. / The safety of Bosutinib for the treatment of chronic myeloid leukemia. In: Expert Opinion on Drug Safety. 2017 ; Vol. 16, No. 10. pp. 1203-1209.
@article{70d0a96ac4b2474a82b7141d46bf2802,
title = "The safety of Bosutinib for the treatment of chronic myeloid leukemia",
abstract = "Introduction: Tyrosine kinase inhibitors (TKIs) are a potentially lifelong treatment for patients with chronic myeloid leukemia (CML). Adverse events (AEs) associated with TKIs are significant impediments in the daily life of patients that can impact compliance, and efficacy. Areas covered: This is a review on safety of bosutinib in the treatment of chronic phase CML. Data is extracted from the latest updates of bosutinib phase I/II and III trials. Expert opinion: Bosutinib is an effective agent against all phases of CML presently approved for the treatment in patients with resistance or intolerance to prior TKI therapy. Bosutinib has a unique toxicity profile characterized by early and transient diarrhea. Otherwise, the AE profile of bosutinib is comparable to other TKIs, with the exception of cardiovascular AEs that are infrequent in bosutinib-treated patients. Similar to other TKIs, the minimum effective dose of bosutinib remains unknown. Better definition of the optimal effective dose may spare, for those patients otherwise benefitting from treatment, unnecessary AEs.",
keywords = "Bosutinib, chronic myeloid leukemia, efficacy, safety",
author = "Kong, {Jee Hyun} and H. Khoury and Kim, {Audrey Sunwha} and Hill, {Brittany Gray} and Vamsi Kota",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/14740338.2017.1363176",
language = "English (US)",
volume = "16",
pages = "1203--1209",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - The safety of Bosutinib for the treatment of chronic myeloid leukemia

AU - Kong, Jee Hyun

AU - Khoury, H.

AU - Kim, Audrey Sunwha

AU - Hill, Brittany Gray

AU - Kota, Vamsi

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: Tyrosine kinase inhibitors (TKIs) are a potentially lifelong treatment for patients with chronic myeloid leukemia (CML). Adverse events (AEs) associated with TKIs are significant impediments in the daily life of patients that can impact compliance, and efficacy. Areas covered: This is a review on safety of bosutinib in the treatment of chronic phase CML. Data is extracted from the latest updates of bosutinib phase I/II and III trials. Expert opinion: Bosutinib is an effective agent against all phases of CML presently approved for the treatment in patients with resistance or intolerance to prior TKI therapy. Bosutinib has a unique toxicity profile characterized by early and transient diarrhea. Otherwise, the AE profile of bosutinib is comparable to other TKIs, with the exception of cardiovascular AEs that are infrequent in bosutinib-treated patients. Similar to other TKIs, the minimum effective dose of bosutinib remains unknown. Better definition of the optimal effective dose may spare, for those patients otherwise benefitting from treatment, unnecessary AEs.

AB - Introduction: Tyrosine kinase inhibitors (TKIs) are a potentially lifelong treatment for patients with chronic myeloid leukemia (CML). Adverse events (AEs) associated with TKIs are significant impediments in the daily life of patients that can impact compliance, and efficacy. Areas covered: This is a review on safety of bosutinib in the treatment of chronic phase CML. Data is extracted from the latest updates of bosutinib phase I/II and III trials. Expert opinion: Bosutinib is an effective agent against all phases of CML presently approved for the treatment in patients with resistance or intolerance to prior TKI therapy. Bosutinib has a unique toxicity profile characterized by early and transient diarrhea. Otherwise, the AE profile of bosutinib is comparable to other TKIs, with the exception of cardiovascular AEs that are infrequent in bosutinib-treated patients. Similar to other TKIs, the minimum effective dose of bosutinib remains unknown. Better definition of the optimal effective dose may spare, for those patients otherwise benefitting from treatment, unnecessary AEs.

KW - Bosutinib

KW - chronic myeloid leukemia

KW - efficacy

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85029544253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029544253&partnerID=8YFLogxK

U2 - 10.1080/14740338.2017.1363176

DO - 10.1080/14740338.2017.1363176

M3 - Article

C2 - 28774214

AN - SCOPUS:85029544253

VL - 16

SP - 1203

EP - 1209

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 10

ER -